Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Universal Sequencing Technology
Canton, Massachusetts, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Universal Sequencing Technology commercializes TELL-Seq, a linked-read sequencing platform that empowers standard short-read sequencers to generate ultra-long-range genomic data. This technology is used for research applications such as de novo whole genome sequencing, metagenomics, whole-genome phasing, and structural variation detection, offering proven accuracy and low DNA input requirements.
- Industry
- Molecular Diagnostics
02
Partnerships
IlluminaTATAA BiocenterSage Science
Beyond the preview
Go deeper on Universal Sequencing Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal Sequencing Technology.